Skip to main content Skip to footer
HomeHome
 
  • Homepage
  • Searching for patents

    Patent knowledge

    Access our patent databases and search tools.

    Go to overview 

    • Overview
    • Technical information
      • Overview
      • Espacenet - patent search
      • European Publication Server
      • EP full-text search
    • Legal information
      • Overview
      • European Patent Register
      • European Patent Bulletin
      • European Case Law Identifier sitemap
      • Third-party observations
    • Business information
      • Overview
      • PATSTAT
      • IPscore
      • Technology insight reports
    • Data
      • Overview
      • Technology Intelligence Platform
      • Linked open EP data
      • Bulk data sets
      • Web services
      • Coverage, codes and statistics
    • Technology platforms
      • Overview
      • Plastics in transition
      • Water innovation
      • Space innovation
      • Technologies combatting cancer
      • Firefighting technologies
      • Clean energy technologies
      • Fighting coronavirus
    • Helpful resources
      • Overview
      • First time here?
      • Asian patent information
      • Patent information centres
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
    Image
    Plastics in Transition

    Technology insight report on plastic waste management

  • Applying for a patent

    Applying for a patent

    Practical information on filing and grant procedures.

    Go to overview 

    • Overview
    • European route
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
      • Appeals
      • Unitary Patent & Unified Patent Court
      • National validation
      • Request for extension/validation
    • International route (PCT)
      • Overview
      • Euro-PCT Guide – PCT procedure at the EPO
      • EPO decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
      • Training and events
    • National route
    • Find a professional representative
    • MyEPO services
      • Overview
      • Understand our services
      • Get access
      • File with us
      • Interact with us on your files
      • Online Filing & fee payment outages
    • Forms
      • Overview
      • Request for examination
    • Fees
      • Overview
      • European fees (EPC)
      • International fees (PCT)
      • Unitary Patent fees (UP)
      • Fee payment and refunds
      • Warning

    UP

    Find out how the Unitary Patent can enhance your IP strategy

  • Law & practice

    Law & practice

    European patent law, the Official Journal and other legal texts.

    Go to overview 

    • Overview
    • Legal texts
      • Overview
      • European Patent Convention
      • Official Journal
      • Guidelines
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
      • Unitary patent system
      • National measures relating to the Unitary Patent
    • Court practices
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
    Image
    Law and practice scales 720x237

    Keep up with key aspects of selected BoA decisions with our monthly "Abstracts of decisions”

  • News & events

    News & events

    Our latest news, podcasts and events, including the European Inventor Award.

    Go to overview 

     

    • Overview
    • News
    • Events
    • European Inventor Award
      • Overview
      • The meaning of tomorrow
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • European Inventor Network
      • The 2024 event
    • Young Inventors Prize
      • Overview
      • About the prize
      • Nominations
      • The jury
      • The world, reimagined
    • Press centre
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • Innovation and patenting in focus
      • Overview
      • Water-related technologies
      • CodeFest
      • Green tech in focus
      • Research institutes
      • Women inventors
      • Lifestyle
      • Space and satellites
      • The future of medicine
      • Materials science
      • Mobile communications
      • Biotechnology
      • Patent classification
      • Digital technologies
      • The future of manufacturing
      • Books by EPO experts
    • "Talk innovation" podcast

    Podcast

    From ideas to inventions: tune into our podcast for the latest in tech and IP

  • Learning

    Learning

    The European Patent Academy – the point of access to your learning

    Go to overview 

    • Overview
    • Learning activities and paths
      • Overview
      • Learning activities
      • Learning paths
    • EQE and EPAC
      • Overview
      • EQE - European qualifying examination
      • EPAC - European patent administration certification
      • CSP – Candidate Support Programme
    • Learning resources by area of interest
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by profile
      • Overview
      • Business and IP managers
      • EQE and EPAC Candidates
      • Judges, lawyers and prosecutors
      • National offices and IP authorities
      • Patent attorneys and paralegals
      • Universities, research centres and technology transfer centres (TTOs)
    Image
    Patent Academy catalogue

    Have a look at the extensive range of learning opportunities in the European Patent Academy training catalogue

  • About us

    About us

    Find out more about our work, values, history and vision

    Go to overview 

    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Overview
      • Official celebrations
      • Member states’ video statements
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Overview
      • Legal foundations
      • Member states of the European Patent Organisation
      • Extension states
      • Validation states
    • Administrative Council and subsidiary bodies
      • Overview
      • Communiqués
      • Calendar
      • Documents and publications
      • Administrative Council
    • Principles & strategy
      • Overview
      • Our mission, vision, values and corporate policy
      • Strategic Plan 2028
      • Towards a New Normal
    • Leadership & management
      • Overview
      • President António Campinos
      • Management Advisory Committee
    • Sustainability at the EPO
      • Overview
      • Environmental
      • Social
      • Governance and Financial sustainability
    • Services & activities
      • Overview
      • Our services & structure
      • Quality
      • Consulting our users
      • European and international co-operation
      • European Patent Academy
      • Chief Economist
      • Ombuds Office
      • Reporting wrongdoing
    • Observatory on Patents and Technology
      • Overview
      • Technologies
      • Innovation actors
      • Policy and funding
      • Tools
      • About the Observatory
    • Procurement
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • Sustainable Procurement Policy
      • About eTendering and electronic signatures
      • Procurement portal
      • Invoicing
      • General conditions
      • Archived tenders
    • Transparency portal
      • Overview
      • General
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Overview
      • Statistics & Trends Centre
      • Patent Index 2024
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Art collection
      • Overview
      • The collection
      • Let's talk about art
      • Artists
      • Media library
      • What's on
      • Publications
      • Contact
      • Culture Space A&T 5-10
      • "Long Night"
    Image
    Patent Index 2024 keyvisual showing brightly lit up data chip, tinted in purple, bright blue

    Track the latest tech trends with our Patent Index

 
en de fr
  • Language selection
  • English
  • Deutsch
  • Français
Main navigation
  • Homepage
    • Go back
    • New to patents
  • New to patents
    • Go back
    • Your business and patents
    • Why do we have patents?
    • What's your big idea?
    • Are you ready?
    • What to expect
    • How to apply for a patent
    • Is it patentable?
    • Are you first?
    • Patent quiz
    • Unitary patent video
  • Searching for patents
    • Go back
    • Overview
    • Technical information
      • Go back
      • Overview
      • Espacenet - patent search
        • Go back
        • Overview
        • National patent office databases
        • Global Patent Index (GPI)
        • Release notes
      • European Publication Server
        • Go back
        • Overview
        • Release notes
        • Cross-reference index for Euro-PCT applications
        • EP authority file
        • Help
      • EP full-text search
    • Legal information
      • Go back
      • Overview
      • European Patent Register
        • Go back
        • Overview
        • Release notes archive
        • Register documentation
          • Go back
          • Overview
          • Deep link data coverage
          • Federated Register
          • Register events
      • European Patent Bulletin
        • Go back
        • Overview
        • Download Bulletin
        • EP Bulletin search
        • Help
      • European Case Law Identifier sitemap
      • Third-party observations
    • Business information
      • Go back
      • Overview
      • PATSTAT
      • IPscore
        • Go back
        • Release notes
      • Technology insight reports
    • Data
      • Go back
      • Overview
      • Technology Intelligence Platform
      • Linked open EP data
      • Bulk data sets
        • Go back
        • Overview
        • Manuals
        • Sequence listings
        • National full-text data
        • European Patent Register data
        • EPO worldwide bibliographic data (DOCDB)
        • EP full-text data
        • EPO worldwide legal event data (INPADOC)
        • EP bibliographic data (EBD)
        • Boards of Appeal decisions
      • Web services
        • Go back
        • Overview
        • Open Patent Services (OPS)
        • European Publication Server web service
      • Coverage, codes and statistics
        • Go back
        • Weekly updates
        • Updated regularly
    • Technology platforms
      • Go back
      • Overview
      • Plastics in transition
        • Go back
        • Overview
        • Plastics waste recovery
        • Plastics waste recycling
        • Alternative plastics
      • Innovation in water technologies
        • Go back
        • Overview
        • Clean water
        • Protection from water
      • Space innovation
        • Go back
        • Overview
        • Cosmonautics
        • Space observation
      • Technologies combatting cancer
        • Go back
        • Overview
        • Prevention and early detection
        • Diagnostics
        • Therapies
        • Wellbeing and aftercare
      • Firefighting technologies
        • Go back
        • Overview
        • Detection and prevention of fires
        • Fire extinguishing
        • Protective equipment
        • Post-fire restoration
      • Clean energy technologies
        • Go back
        • Overview
        • Renewable energy
        • Carbon-intensive industries
        • Energy storage and other enabling technologies
      • Fighting coronavirus
        • Go back
        • Overview
        • Vaccines and therapeutics
          • Go back
          • Overview
          • Vaccines
          • Overview of candidate therapies for COVID-19
          • Candidate antiviral and symptomatic therapeutics
          • Nucleic acids and antibodies to fight coronavirus
        • Diagnostics and analytics
          • Go back
          • Overview
          • Protein and nucleic acid assays
          • Analytical protocols
        • Informatics
          • Go back
          • Overview
          • Bioinformatics
          • Healthcare informatics
        • Technologies for the new normal
          • Go back
          • Overview
          • Devices, materials and equipment
          • Procedures, actions and activities
          • Digital technologies
        • Inventors against coronavirus
    • Helpful resources
      • Go back
      • Overview
      • First time here?
        • Go back
        • Overview
        • Basic definitions
        • Patent classification
          • Go back
          • Overview
          • Cooperative Patent Classification (CPC)
        • Patent families
          • Go back
          • Overview
          • DOCDB simple patent family
          • INPADOC extended patent family
        • Legal event data
          • Go back
          • Overview
          • INPADOC classification scheme
      • Asian patent information
        • Go back
        • Overview
        • China (CN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Chinese Taipei (TW)
          • Go back
          • Overview
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • India (IN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
        • Japan (JP)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Korea (KR)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Russian Federation (RU)
          • Go back
          • Overview
          • Facts and figures
          • Numbering system
          • Searching in databases
        • Useful links
      • Patent information centres (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
  • Applying for a patent
    • Go back
    • Overview
    • European route
      • Go back
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
        • Go back
        • Oral proceedings calendar
          • Go back
          • Calendar
          • Public access to appeal proceedings
          • Public access to opposition proceedings
          • Technical guidelines
      • Appeals
      • Unitary Patent & Unified Patent Court
        • Go back
        • Overview
        • Unitary Patent
          • Go back
          • Overview
          • Legal framework
          • Main features
          • Applying for a Unitary Patent
          • Cost of a Unitary Patent
          • Translation and compensation
          • Start date
          • Introductory brochures
        • Unified Patent Court
      • National validation
      • Extension/validation request
    • International route
      • Go back
      • Overview
      • Euro-PCT Guide
      • Entry into the European phase
      • Decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
        • Go back
        • Patent Prosecution Highway (PPH) programme outline
      • Training and events
    • National route
    • MyEPO services
      • Go back
      • Overview
      • Understand our services
        • Go back
        • Overview
        • Exchange data with us using an API
          • Go back
          • Release notes
      • Get access
        • Go back
        • Overview
        • Release notes
      • File with us
        • Go back
        • Overview
        • What if our online filing services are down?
        • Release notes
      • Interact with us on your files
        • Go back
        • Release notes
      • Online Filing & fee payment outages
    • Fees
      • Go back
      • Overview
      • European fees (EPC)
        • Go back
        • Overview
        • Decisions and notices
      • International fees (PCT)
        • Go back
        • Reduction in fees
        • Fees for international applications
        • Decisions and notices
        • Overview
      • Unitary Patent fees (UP)
        • Go back
        • Overview
        • Decisions and notices
      • Fee payment and refunds
        • Go back
        • Overview
        • Payment methods
        • Getting started
        • FAQs and other documentation
        • Technical information for batch payments
        • Decisions and notices
        • Release notes
      • Warning
    • Forms
      • Go back
      • Overview
      • Request for examination
    • Find a professional representative
  • Law & practice
    • Go back
    • Overview
    • Legal texts
      • Go back
      • Overview
      • European Patent Convention
        • Go back
        • Overview
        • Archive
          • Go back
          • Overview
          • Documentation on the EPC revision 2000
            • Go back
            • Overview
            • Diplomatic Conference for the revision of the EPC
            • Travaux préparatoires
            • New text
            • Transitional provisions
            • Implementing regulations to the EPC 2000
            • Rules relating to Fees
            • Ratifications and accessions
          • Travaux Préparatoires EPC 1973
      • Official Journal
      • Guidelines
        • Go back
        • Overview
        • EPC Guidelines
        • PCT-EPO Guidelines
        • Unitary Patent Guidelines
        • Guidelines revision cycle
        • Consultation results
        • Summary of user responses
        • Archive
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
        • Go back
        • Overview
        • Archive
      • Unitary Patent system
        • Go back
        • Travaux préparatoires to UP and UPC
      • National measures relating to the Unitary Patent 
    • Court practices
      • Go back
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Go back
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Go back
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
  • News & events
    • Go back
    • Overview
    • News
    • Events
    • European Inventor Award
      • Go back
      • Overview
      • The meaning of tomorrow
      • About the award
      • Categories and prizes
      • Meet the inventors
      • Nominations
      • European Inventor Network
        • Go back
        • 2024 activities
        • 2025 activities
        • Rules and criteria
        • FAQ
      • The 2024 event
    • Young Inventors Prize
      • Go back
      • Overview
      • About the prize
      • Nominations
      • The jury
      • The world, reimagined
      • The 2025 event
    • Press centre
      • Go back
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
        • Go back
        • Overview
        • European Patent Office
        • Q&A on patents related to coronavirus
        • Q&A on plant patents
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • In focus
      • Go back
      • Overview
      • Water-related technologies
      • CodeFest
        • Go back
        • CodeFest Spring 2025 on classifying patent data for sustainable development
        • Overview
        • CodeFest 2024 on generative AI
        • CodeFest 2023 on Green Plastics
      • Green tech in focus
        • Go back
        • Overview
        • About green tech
        • Renewable energies
        • Energy transition technologies
        • Building a greener future
      • Research institutes
      • Women inventors
      • Lifestyle
      • Space and satellites
        • Go back
        • Overview
        • Patents and space technologies
      • Healthcare
        • Go back
        • Overview
        • Medical technologies and cancer
        • Personalised medicine
      • Materials science
        • Go back
        • Overview
        • Nanotechnology
      • Mobile communications
      • Biotechnology
        • Go back
        • Overview
        • Red, white or green
        • The role of the EPO
        • What is patentable?
        • Biotech inventors
      • Classification
        • Go back
        • Overview
        • Nanotechnology
        • Climate change mitigation technologies
          • Go back
          • Overview
          • External partners
          • Updates on Y02 and Y04S
      • Digital technologies
        • Go back
        • Overview
        • About ICT
        • Hardware and software
        • Artificial intelligence
        • Fourth Industrial Revolution
      • Additive manufacturing
        • Go back
        • Overview
        • About AM
        • AM innovation
      • Books by EPO experts
    • Podcast
  • Learning
    • Go back
    • Overview
    • Learning activities and paths
      • Go back
      • Overview
      • Learning activities: types and formats
      • Learning paths
    • EQE and EPAC
      • Go back
      • Overview
      • EQE - European Qualifying Examination
        • Go back
        • Overview
        • Compendium
          • Go back
          • Overview
          • Paper F
          • Paper A
          • Paper B
          • Paper C
          • Paper D
          • Pre-examination
        • Candidates successful in the European qualifying examination
        • Archive
      • EPAC - European patent administration certification
      • CSP – Candidate Support Programme
    • Learning resources by area of interest
      • Go back
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by profile
      • Go back
      • Overview
      • Business and IP managers
        • Go back
        • Overview
        • Innovation case studies
          • Go back
          • Overview
          • SME case studies
          • Technology transfer case studies
          • High-growth technology case studies
        • Inventor's handbook
          • Go back
          • Overview
          • Introduction
          • Disclosure and confidentiality
          • Novelty and prior art
          • Competition and market potential
          • Assessing the risk ahead
          • Proving the invention
          • Protecting your idea
          • Building a team and seeking funding
          • Business planning
          • Finding and approaching companies
          • Dealing with companies
        • Best of search matters
          • Go back
          • Overview
          • Tools and databases
          • EPO procedures and initiatives
          • Search strategies
          • Challenges and specific topics
        • Support for high-growth technology businesses
          • Go back
          • Overview
          • Business decision-makers
          • IP professionals
          • Stakeholders of the Innovation Ecosystem
      • EQE and EPAC Candidates
        • Go back
        • Overview
        • Paper F brain-teasers
        • Daily D questions
        • European qualifying examination - Guide for preparation
        • EPAC
      • Judges, lawyers and prosecutors
        • Go back
        • Overview
        • Compulsory licensing in Europe
        • The jurisdiction of European courts in patent disputes
      • National offices and IP authorities
        • Go back
        • Overview
        • Learning material for examiners of national officers
        • Learning material for formalities officers and paralegals
      • Patent attorneys and paralegals
      • Universities, research centres and TTOs
        • Go back
        • Overview
        • Modular IP Education Framework (MIPEF)
        • Pan-European Seal Young Professionals Programme
          • Go back
          • Overview
          • For students
          • For universities
            • Go back
            • Overview
            • IP education resources
            • University memberships
          • Our young professionals
          • Professional development plan
        • Academic Research Programme
          • Go back
          • Overview
          • Completed research projects
          • Current research projects
        • IP Teaching Kit
          • Go back
          • Overview
          • Download modules
        • Intellectual property course design manual
        • PATLIB Knowledge Transfer to Africa
          • Go back
          • The PATLIB Knowledge Transfer to Africa initiative (KT2A)
          • KT2A core activities
          • Success story: Malawi University of Science and Technology and PATLIB Birmingham
  • About us
    • Go back
    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Go back
      • Official celebrations
      • Overview
      • Member states’ video statements
        • Go back
        • Albania
        • Austria
        • Belgium
        • Bulgaria
        • Croatia
        • Cyprus
        • Czech Republic
        • Denmark
        • Estonia
        • Finland
        • France
        • Germany
        • Greece
        • Hungary
        • Iceland
        • Ireland
        • Italy
        • Latvia
        • Liechtenstein
        • Lithuania
        • Luxembourg
        • Malta
        • Monaco
        • Montenegro
        • Netherlands
        • North Macedonia
        • Norway
        • Poland
        • Portugal
        • Romania
        • San Marino
        • Serbia
        • Slovakia
        • Slovenia
        • Spain
        • Sweden
        • Switzerland
        • Türkiye
        • United Kingdom
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Go back
      • Overview
      • Legal foundations
      • Member states
        • Go back
        • Overview
        • Member states by date of accession
      • Extension states
      • Validation states
    • Administrative Council and subsidiary bodies
      • Go back
      • Overview
      • Communiqués
        • Go back
        • 2024
        • Overview
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
        • 2013
      • Calendar
      • Documents and publications
        • Go back
        • Overview
        • Select Committee documents
      • Administrative Council
        • Go back
        • Overview
        • Composition
        • Representatives
        • Rules of Procedure
        • Board of Auditors
        • Secretariat
        • Council bodies
    • Principles & strategy
      • Go back
      • Overview
      • Mission, vision, values & corporate policy
      • Strategic Plan 2028
        • Go back
        • Driver 1: People
        • Driver 2: Technologies
        • Driver 3: High-quality, timely products and services
        • Driver 4: Partnerships
        • Driver 5: Financial sustainability
      • Towards a New Normal
      • Data protection & privacy notice
    • Leadership & management
      • Go back
      • Overview
      • About the President
      • Management Advisory Committee
    • Sustainability at the EPO
      • Go back
      • Overview
      • Environmental
        • Go back
        • Overview
        • Inspiring environmental inventions
      • Social
        • Go back
        • Overview
        • Inspiring social inventions
      • Governance and Financial sustainability
    • Procurement
      • Go back
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • Dynamic Purchasing System (DPS) publications
      • Sustainable Procurement Policy
      • About eTendering
      • Invoicing
      • Procurement portal
        • Go back
        • Overview
        • e-Signing contracts
      • General conditions
      • Archived tenders
    • Services & activities
      • Go back
      • Overview
      • Our services & structure
      • Quality
        • Go back
        • Overview
        • Foundations
          • Go back
          • Overview
          • European Patent Convention
          • Guidelines for examination
          • Our staff
        • Enabling quality
          • Go back
          • Overview
          • Prior art
          • Classification
          • Tools
          • Processes
        • Products & services
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
          • Continuous improvement
        • Quality through networking
          • Go back
          • Overview
          • User engagement
          • Co-operation
          • User satisfaction survey
          • Stakeholder Quality Assurance Panels
        • Patent Quality Charter
        • Quality Action Plan
        • Quality dashboard
        • Statistics
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
        • Integrated management at the EPO
      • Consulting our users
        • Go back
        • Overview
        • Standing Advisory Committee before the EPO (SACEPO)
          • Go back
          • Overview
          • Objectives
          • SACEPO and its working parties
          • Meetings
          • Single Access Portal – SACEPO Area
        • Surveys
          • Go back
          • Overview
          • Detailed methodology
          • Search services
          • Examination services, final actions and publication
          • Opposition services
          • Formalities services
          • Customer services
          • Filing services
          • Key Account Management (KAM)
          • Website
          • Archive
      • Our user service charter
      • European and international co-operation
        • Go back
        • Overview
        • Co-operation with member states
          • Go back
          • Overview
        • Bilateral co-operation with non-member states
          • Go back
          • Overview
          • Validation system
          • Reinforced Partnership programme
        • Multilateral international co-operation with IP offices and organisations
        • Co-operation with international organisations outside the IP system
      • European Patent Academy
        • Go back
        • Overview
        • Partners
      • Chief Economist
        • Go back
        • Overview
        • Economic studies
      • Ombuds Office
      • Reporting wrongdoing
    • Observatory on Patents and Technology
      • Go back
      • Overview
      • Technologies
        • Go back
        • Overview
        • Innovation against cancer
        • Assistive robotics
        • Space technologies
      • Innovation actors
        • Go back
        • Overview
        • Startups and SMEs
          • Go back
          • Overview
          • Publications
        • Research universities and public research organisations
      • Policy and funding
        • Go back
        • Overview
        • Financing innovation programme
          • Go back
          • Overview
          • Our studies on the financing of innovation
          • EPO initiatives for patent applicants
          • Financial support for innovators in Europe
        • Patents and standards
          • Go back
          • Overview
          • Publications
          • Patent standards explorer
      • Tools
        • Go back
        • Overview
        • Deep Tech Finder
      • About the Observatory
        • Go back
        • Overview
        • Work plan
    • Transparency portal
      • Go back
      • Overview
      • General
        • Go back
        • Overview
        • Annual Review 2023
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • 50 years of the EPC
          • Strategic key performance indicators
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
        • Annual Review 2022
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Go back
      • Overview
      • Statistics & Trends Centre
      • Patent Index 2024
        • Go back
        • Insight into computer technology and AI
        • Insight into clean energy technologies
        • Statistics and indicators
          • Go back
          • European patent applications
            • Go back
            • Key trend
            • Origin
            • Top 10 technical fields
              • Go back
              • Computer technology
              • Electrical machinery, apparatus, energy
              • Digital communication
              • Medical technology
              • Transport
              • Measurement
              • Biotechnology
              • Pharmaceuticals
              • Other special machines
              • Organic fine chemistry
            • All technical fields
          • Applicants
            • Go back
            • Top 50
            • Categories
            • Women inventors
          • Granted patents
            • Go back
            • Key trend
            • Origin
            • Designations
      • Data to download
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Go back
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Art collection
      • Go back
      • Overview
      • The collection
      • Let's talk about art
      • Artists
      • Media library
      • What's on
      • Publications
      • Contact
      • Culture Space A&T 5-10
        • Go back
        • Catalyst lab & Deep vision
          • Go back
          • Irene Sauter (DE)
          • AVPD (DK)
          • Jan Robert Leegte (NL)
          • Jānis Dzirnieks (LV) #1
          • Jānis Dzirnieks (LV) #2
          • Péter Szalay (HU)
          • Thomas Feuerstein (AT)
          • Tom Burr (US)
          • Wolfgang Tillmans (DE)
          • TerraPort
          • Unfinished Sculpture - Captives #1
          • Deep vision – immersive exhibition
          • Previous exhibitions
        • The European Patent Journey
        • Sustaining life. Art in the climate emergency
        • Next generation statements
        • Open storage
        • Cosmic bar
      • "Long Night"
  • Boards of Appeal
    • Go back
    • Overview
    • Decisions of the Boards of Appeal
      • Go back
      • Overview
      • Recent decisions
      • Selected decisions
    • Information from the Boards of Appeal
    • Procedure
    • Oral proceedings
    • About the Boards of Appeal
      • Go back
      • Overview
      • President of the Boards of Appeal
      • Enlarged Board of Appeal
        • Go back
        • Overview
        • Pending referrals (Art. 112 EPC)
        • Decisions sorted by number (Art. 112 EPC)
        • Pending petitions for review (Art. 112a EPC)
        • Decisions on petitions for review (Art. 112a EPC)
      • Technical Boards of Appeal
      • Legal Board of Appeal
      • Disciplinary Board of Appeal
      • Presidium
        • Go back
        • Overview
    • Code of Conduct
    • Business distribution scheme
      • Go back
      • Overview
      • Technical boards of appeal by IPC in 2025
      • Archive
    • Annual list of cases
    • Communications
    • Annual reports
      • Go back
      • Overview
    • Publications
      • Go back
      • Abstracts of decisions
    • Case Law of the Boards of Appeal
      • Go back
      • Overview
      • Archive
  • Service & support
    • Go back
    • Overview
    • Website updates
    • Availability of online services
      • Go back
      • Overview
    • FAQ
      • Go back
      • Overview
    • Publications
    • Ordering
      • Go back
      • Overview
      • Patent Knowledge Products and Services
      • Terms and conditions
        • Go back
        • Overview
        • Patent information products
        • Bulk data sets
        • Open Patent Services (OPS)
        • Fair use charter
    • Procedural communications
    • Useful links
      • Go back
      • Overview
      • Patent offices of member states
      • Other patent offices
      • Directories of patent attorneys
      • Patent databases, registers and gazettes
      • Disclaimer
    • Contact us
      • Go back
      • Overview
      • Filing options
      • Locations
    • Subscription centre
      • Go back
      • Overview
      • Subscribe
      • Change preferences
      • Unsubscribe
    • Official holidays
    • Glossary
    • RSS feeds
Board of Appeals
Decisions

Recent decisions

Overview
  • 2025 decisions
  • 2024 decisions
  • 2023 decisions
  1. Home
  2. T 0904/98 (Dermal Aspirin/GUNDERSON) 20-07-2000
Facebook X Linkedin Email

T 0904/98 (Dermal Aspirin/GUNDERSON) 20-07-2000

European Case Law Identifier
ECLI:EP:BA:2000:T090498.20000720
Date of decision
20 July 2000
Case number
T 0904/98
Petition for review of
-
Application number
92912205.9
IPC class
A61K 31/60
Language of proceedings
EN
Distribution
DISTRIBUTED TO BOARD CHAIRMEN (C)

Download and more information:

Decision in EN 39.25 KB
Documentation of the appeal procedure can be found in the European Patent Register
Bibliographic information is available in:
EN
Versions
Unpublished
Application title

Suppression of thromboxane levels by percutaneous administration of aspirin

Applicant name
GUNDERSON MEDICAL FOUNDATION, LTD. et al
Opponent name
-
Board
3.3.02
Headnote
-
Relevant legal provisions
European Patent Convention Art 52(1) 1973
European Patent Convention Art 54 1973
European Patent Convention Art 56 1973
Keywords

Novelty (yes)

Inventive step (yes); non-obvious solution; finding that dermal aspirin does not affect prostaglandin levels, while effectively suppressing thromboxane levels in a mammalian subject, not a mere bonus effect, but achievement of a desirable therapeutic goal in its own right

Catchword
-
Cited decisions
G 0005/83
Citing decisions
-

I. European patent application No. 92 912 205.9, published as WO 92/20 343, was refused under Article 97(1) EPC by a decision of the examining division posted on 23 April 1998. The decision was based on claims 1 to 16 filed during oral proceedings held on 13 March 1997. Claim 1 was worded as follows:

"Use of aspirin for the manufacture of a pharmaceutical preparation for suppressing thromboxane levels in a mammalian subject without affecting prostacyclin levels or resulting in gastrointestinal toxicity, the pharmaceutical preparation comprising aspirin and a support for maintaining said aspirin in a form for percutaneous absorption by said skin, wherein said aspirin is present in an amount sufficient to reduce thromboxane levels in said subject by more than 50%."

Dependent claims 2 to 16 related to specific elaborations of the use according to claim 1.

II. In the course of the proceedings before the examining division reference was made, inter alia, to the following documents:

(1) Naito et al. "Percutaneous Absorption of Salicylic Acid Derivatives" published in Japanese Pharmacology & Therapeutics, vol. 16, no. 1, 1988, pages 17 to 25

(3) FR-A 2 295 753

(4) J. Hirsh et al. "Aspirin and Other Platelet Active Drugs" published in Chest, vol. 95, no. 2, 1989, pages 12S to 18S)

(5) WO 91/00096

III. The stated ground for the refusal was that the invention did not involve an inventive step, having regard to the disclosure in citation (5), and in particular also in citation (1). The substance of the reasoning given in the decision of the examining division was as follows:

The present application and the closest state of the art, which was citation (5), sought to solve essentially the same problem, this problem being the suppression of thromboxane levels and platelet aggregation in the human blood system by the administration of aspirin via a non-oral route, in order to avoid adverse side effects such as gastrointestinal disorders. In the state of the art according to (5) it was proposed to solve this problem by the administration of aspirin in the form of a sublingual lozenge.

Since, in the opinion of the examining division, citation (1) suggested to a person skilled in the art that the percutaneous administration of aspirin according to present claim 1 was a promising alternative to the sublingual administration disclosed in (5), the proposed solution of the above-identified problem was considered to be the result of an obvious combination of the teachings of citations (1) and (5).

IV. The appellant (applicant) lodged an appeal against this decision. The statement of grounds was accompanied by two declarations of the joint inventors of the present application, Mr Rudolph M. Keimowitz and Mr Desmond J. Fitzgerald.

V. At the beginning of the oral proceedings, held on 20. July 2000, the appellant submitted in substitution for all previously filed requests a revised set of claims forming the sole remaining request. Claims 1 to 15. of this request correspond to claims 1 to 10 and 12 to 16 filed on 13 March 1997 during the oral proceedings before the examining division (see paragraph I supra).

VI. The appellant's submissions presented in writing and during oral proceedings can be summarised as follows:

Since with sublingual administration of aspirin, as disclosed in citation (5), the dosage was primarily received when the patient swallowed saliva containing the dissolved drug, the cited document failed, contrary to the assertion of the examining division, to teach administering aspirin to the blood plasma by a non-oral route. In both oral and sub-lingual administration, the drug was released into the bloodstream only after its contact with the gastrointestinal tract. Thus, (5) provided no evidence that gastric disturbance was avoided or effectively reduced by sublingual aspirin dosage.

Citation (1) did disclose percutaneous administration of aspirin, but provided no teaching or suggestion as to potential uses of such dermal aspirin, much less whether percutaneous administration was even feasible or desirable for lowering thromboxane levels. By comparison, citation (3) pertained to percutaneous administration of aspirin, but with treatment solely directed to analgesic effects.

The mode of action of aspirin for effecting analgesia was very different from that for lowering thromboxane levels. Whereas an effective antithrombotic therapy required the release of sufficient quantities of aspirin in its intact, acetylated form into the bloodstream, an acetyl group was not necessary when aspirin was used for the treatment of analgesia.

In fact, aspirin was known to be very unstable, having a short biological half-life in systemic circulation and being quickly hydrolyzed to salicylic acid in the gastrointestinal tract. Contrary to the finding of the examining division, citation (1) in no way taught that intact aspirin reached the bloodstream after percutaneous administration. In particular, the authors of (1) never measured the quantities of intact acetyl salicylic acid in blood plasma. What they actually measured in (1) were the quantities of the drug as salicylic acid following oral or dermal administration of aspirin.

The features "without substantially affecting prostacyclin levels or resulting in gastrointestinal toxicity" were not merely "bonus effects" but were part of the problem that was addressed and solved by the appellant's invention. In view of the known instability of acetyl salicylic acid it was unexpected that dermal aspirin could be absorbed through the skin in its intact acetylated form in sufficient quantities and with sufficient stability to lower thromboxane levels by more than 50% without substantially affecting prostacyclin levels or resulting in gastrointestinal disorders.

VII. The appellant requests that the decision under appeal be set aside and a patent be granted on the basis of the "Main Request" (being the only request) filed during the oral proceedings.

1. The appeal is admissible.

2. Claims 1 to 17 as originally filed were directed to a method for inducing thromboxane suppression by percutaneously administering aspirin (acetyl salicylic acid) to a mammalian subject. Since such claims would fall under the prohibition of Article 52(4) EPC, during the proceedings before the examining division, all claims were drafted in the form for the protection of the "second or further medical indication" of a medicament, according to decision G 5/83 (OJ EPO, 1985, 64).

2.1. All references below to support for the present version of the claims in the application as filed are to the international application as published under the PCT (WO 92/20343). In particular:

the feature being additionally included in claim 1 "sufficient to reduce thromboxane levels by more than 50%" is taken from page 6, lines 3 to 4;

the feature "without affecting prostacyclin levels" finds its support in claim 12 as originally filed in conjunction with the disclosure in the paragraph bridging pages 6 and 7 and Example 3;

the feature "without resulting in gastrointestinal toxicity" finds its counterpart on page 5, lines 8 to 9; dependent claim 2 is based on the embodiments described on page 5, lines 17 to 20 and dependent claim 13 on those described on page 3, line 23;

dependent claims 3 to 12, 14 and 15 are based on the original ones in the following order:

- present claims: 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 15

- original claims: 5, 3, 4, 8, 9, 10, 11, 13, 14, 16, 6, 7.

2.2. All claims are therefore acceptable as being supported by the disclosure of the application as filed and complying in this formal respect with Articles 84 and 123(2) EPC.

3. The invention relates to the use of aspirin in a galenic formulation suitable for percutaneous administration (hereinafter referred to as "dermal aspirin") as a medicament for reducing thromboxane levels in a mammalian subject by more than 50% without simultaneously affecting prostacyclin levels or causing gastrointestinal disorders. The medicament is thereby applied topically to a patient's skin such that aspirin is percutaneously absorbed into the blood stream to achieve the desired therapeutic effect. The galenic formulation of the medicament used for this treatment comprises a support or carrier which is conventionally used for the application of topical agents, preferably propylene glycol, and which contains the aspirin in a solubilized form, optionally along with other active agents and pharmaceutically acceptable adjuvants. The medicament preferably used in the present application contains approximately 9% aspirin (see page 5, lines 17 to 30; page 10, lines 15 to 21; claims 1 to 3).

3.1. Having regard to the state of the art known from the documents available in the proceedings, it has to be decided, in the board's judgement, whether citation (5), relied on by the examining division in the decision under appeal as the closest state of the art, or citation (3), cited in the search report and referred to as relevant state of the art in the official communications of the examining division of 11. November 1996 and 30 June 1997, comes closer to the claimed subject-matter of the application.

3.2. Citation (5) seeks to overcome certain well known problems arising from the deacetylation of aspirin in the gastrointestinal tract (ie conversion of acetyl salicylic acid to salicylic acid) to a variable but significant extent in different individuals following its oral administration. The major problems addressed in (5) concern in general the increased tendency of deacetylated or partially deacetylated aspirin to cause gastrointestinal disorders, stomach irritation, ulcers, etc. and, more specifically, its reduced capability or even incapability effectively to suppress thromboxane levels and control platelet aggregation in the human blood system (see especially page 1, penultimate paragraph to page 3, line 11).

Although the problems mentioned above have clearly been recognised in (5) as being primarily caused by oral administration of aspirin, the solution offered in (5) was simply the provision of a tablet containing a relatively small amount of aspirin capable of rapid dissolution or disintegration in the oral, preferably sublingual, cavity. The board concurs with the statement in Mr. Keimowitz' declaration to the effect that, with sublingual administration of aspirin as disclosed in citation (5), the dosage is primarily received when the patient swallows saliva containing the dissolved drug and that accordingly (5) provided no evidence as to whether gastric disturbance is effectively reduced by sublingual aspirin dosage which is in fact merely a specific galenic formulation of oral aspirin.

3.3. On the other hand citation (3) does actually pertain to the use of dermal aspirin as an advantageous alternative to oral dosage forms of aspirin for certain therapeutic applications. The medicament disclosed in (3) comprises aspirin in an amount of 1 to 25% by weight solubilized in a liquid or glutinous carrier or support which is selected from those conventionally used for the application of topical agents, for example, different sorts of hydrogenated vegetable fats or polyoxyethylene glycols.

Hence, comparison of the invention, as outlined in point 3 supra, with the prior art of (3), establishes that the medicament used in (3) does not differ from that in the present application with regard to

- the active agent of the medicament,

- the medicament's galenic formulation,

- the mode of its administration and

- the benefits arising from the dermal aspirin bypassing the gastrointestinal tract, thereby eliminating or at least reducing the risk of gastrointestinal side effects, including bleeding.

The sole difference consists in the proposed intended therapeutic application of the medicament. According to (3), dermal aspirin has an indisputable quality as an anti-inflammatory or analgesic agent and can be used to treat all sorts of localized pains normally requiring a local treatment, such as rheumatism, arthritis, traumatism, stiffness and contusions as well as in the treatment of burns, such as sunburns, rushes, insect stings, small wounds, etc (see (3): page 3, lines 20 to 31).

3.4. In view of the foregoing considerations, the board reaches the conclusion that the disclosure of (3), relating to dermal aspirin as a medicament in a suitable galenic form for various therapeutic applications, comes closer to the subject-matter of the invention than the disclosure of any other cited document, including citation (5), which essentially teaches an improved method of oral administration of aspirin. Taking into account that the sole difference between the prior art of (3) and the claimed invention resides in the different therapeutic application of the same medicament and, moreover, that the claims, as they now stand, are directed to the protection of a "second or further therapeutic application" of dermal aspirin, the prior art of (3) is considered to be the most promising starting point to arrive at the claimed subject-matter in the application.

4. Thus, starting from citation (3) as the closest state of the art, the problem to be solved by the present application consists in providing a further therapeutic use or application for dermal aspirin.

According to claim 1 it is suggested to solve this problem by using dermal aspirin as an antithrombotic agent to suppress thromboxane levels in a mammalian subject by more than 50% without simultaneously affecting prostacyclin levels or causing gastrointestinal toxicity.

4.1. The thromboxane level in a mammalian subject is a significant and important physiological parameter that is exactly and easily measurable and recordable by standard diagnostic methods and is indicative of an individual's physiological and clinical risk in cardiovascular and cerebrovascular diseases such as myocardial infarction and stroke [see eg citations (4) and (5)]. Its reduction by more than 50% in a mammalian subject, as required by claim 1, is therefore a precisely defined therapeutic application of dermal aspirin within the meaning of Article 52(4) EPC for the purpose of treating and preventing various diseases benefiting from suppression of thromboxane levels, for example, cerebrovascular and cardiovascular diseases such as ischemic heart disease.

5. After examination of the documents uncovered by the search report and of those introduced during the examination and appeal procedures, the board is satisfied that none of them discloses the specific therapeutic application of dermal aspirin mentioned-above. The subject-matter of the claims is accordingly deemed to be novel within the meaning of Article 54(1) EPC on the basis of the principles set out in decision G 5/83 (loc. cit.). Since the board concurs with the opinion of the examining division in this point, there is no need for further detailed consideration of this issue.

6. The question arises whether the problem defined above has indeed been solved in all its different aspects by the features recited in Claim 1.

6.1. It can be derived from the tabulated test results in Table 1 on page 11 and likewise from Figures 1 and 2 of the specification that five successive daily applications of dermal aspirin in accordance with the application caused in all five subjects tested a decrease in thromboxane levels of at least 50%. The two subjects that continued therapy in accordance with the application for another five days had further marked reduction in thromboxane levels by Day 10 of 95 and 97%.

6.2. Further, from Figure 3 in conjunction with the disclosure in the paragraph bridging pages 6 and 7 of the specification, it can be seen that application of the highest dosage unit of 750 mg/day of dermal aspirin caused, based on urinary PGI-M determinations as an index of in vivo PGI2 biosynthesis, only a small decrease in the prostaglandin (PGI2) level due to a small fall in PGI2 biosynthesis by day 4, while no further reduction occurred despite continued application, and by day 10 the level remained at 83% of baseline. This finding is confirmed by the tabulated test results in Table 2 on page 15 of the specification, which show that, despite the evidence of marked decrease of thromboxane levels (see TX-M pre-ASA vs. TX-M post-ASA), there was no statistically significant change in basal prostacyclin (PGI2) levels (see PGI-M (rest) pre-ASA vs. PGI-M (rest) post-ASA).

Moreover, the data in Table 2 show that PGI2 formation in response to bradykinin infusion was substantially unaltered following dermal aspirin administration at a dose of 750 mg/day. This provides evidence that dermal aspirin did not substantially affect prostacyclin (PGI2) levels (see PGI-M (stim) pre-ASA vs. PGI-M (stim) post-ASA).

In contrast, as can be seen from the comparative data in Table 2, 75mg/day of oral aspirin markedly suppressed both basal (see PGI-M (rest) pre-ASA vs. PGI-M (rest) post-ASA) and bradykinin-stimulated PGI-M excretion (see PGI-M (stim) pre-ASA vs. PGI-M (stim) post-ASA). This provides evidence of a substantial reduction in prostaglandin (PGI2) levels following oral administration of aspirin.

6.3. According to the disclosure on page 12, lines 8 to 10, all hemocults taken from the 5 subjects tested were negative and no gastrointestinal symptoms or other side effects were noted or reported by them.

6.4. Consequently, in view of the results obtained in the examples of the present application and in the absence of any evidence to the contrary, the board is satisfied that the problem in all its different aspects, as defined above, is plausibly solved.

7. It remains to be examined whether, in view of the technical problem to be solved, the requirement of inventive step is met by the claimed use.

7.1. The board concurs with the appellant's submission during oral proceedings that the comparative results shown in citation (1) regarding delivery of dermal aspirin and salicylic acid (see especially Figure 3 (B), 4 (B), 6 and the corresponding text in the paragraph bridging pages 23 and 24) could not result from intact aspirin reaching the bloodstream, but rather from different degrees of retention of aspirin and salicylic acid in the various ointments tested. As indicated at the end of page 23 of (1), the comparative results refer to the level of cutaneous absorption of aspirin and salicylic from the different ointments used.

Contrary to the view of the examining division in the decision under appeal, the board cannot find in citation (1) any teaching or suggestion to the effect that intact aspirin would in fact be capable of reaching the bloodstream following percutaneous absorption. Nowhere is there evidence in (1) that blood plasma levels of intact aspirin have been measured. Further, since the cited document does not refer to any potential use or therapeutic application of such dermal aspirin, the disclosure of (1) is not considered to be relevant to the assessment of inventive step in the present case.

7.2. Although at the publication date (December 1974) of citation (3) at least some evidence was already available to a person skilled in the art that aspirin might be effective as an antithrombotic agent in patients with cerebrovascular disease and ischemic heart disease [see eg (4): references 19, 57, 61, 62], the disclosure of (3) is entirely silent as to any possible antithrombotic effect of dermal aspirin or its potential use to suppress thromboxane levels or control platelet aggregation in the human blood system.

At the priority date, however, aspirin had become widely used as an antithrombotic agent to treat a broad spectrum of medical conditions benefiting from suppression of thromboxane levels. The skilled person also knew that aspirin causes the lowering of thromboxane levels by irreversibly acetylating the enzyme cyclooxygenase. Thus the acetyl group of aspirin, while not required to exhibit its analgesic effect, is necessary for lowering thromboxane levels, as is described, for example, in documents (4) and (5).

7.3. The skilled person with this knowledge seeking to solve the technical problem, would certainly have noticed that the detection of the presence of acetyl salicylic acid (aspirin) in the urine following the administration of dermal aspirin was taken in (3) as an evidence that acetyl salicylic acid was capable of passing the skin barrier (see especially page 4, lines 20 to 24).

The question that arises is whether the skilled person would have arrived at the claimed solution of the stated problem by considering the above-mentioned disclosure in citation (3). In answering this question the board notes that the presence of intact aspirin in the bloodstream is not described and cannot, at least not explicitly, be derived from the disclosure of (3), much less whether percutaneous administration would even be feasible or desirable for lowering thromboxane levels. In this respect it must also be kept in mind that acetyl salicylic acid was applied in (3) for analgesia (pain relief) only, for which an acetyl group is not necessary to achieve the desired therapeutic effect. The information given in (3) must, moreover, be considered in the context of the skilled person's general knowledge at the priority date that the ester linkage between the acetyl group and the salicylic acid molecule is easily broken and that the absorbed aspirin is readily metabolized to the largely inactive salicylate by esterases present in the skin tissue and physiological fluids, such as blood and water, before it reaches systemic vasculature.

In the light of the considerations set out above, the board concludes that the actual information derivable from (3) must be considered too vague and general to point the skilled person positively in the direction of the claimed invention. Even if he had conceivably learned from (3) the basic capability of dermal aspirin to pass the skin barrier in an entirely unspecified amount or concentration, the disclosure of (3) fails to provide any useful suggestion whatsoever as to the quantities of acetyl salicylic acid effectively absorbed into the bloodstream through the skin, let alone as to whether such quantities would be sufficient to reduce thromboxane levels by more than 50% as required in claim 1.

7.4. Moreover, the adequate solution to the stated problem not only requires the reduction of thromboxane levels by more than 50% but also their selective reduction without simultaneously affecting to any significant extent vascular prostacyclin activity and, accordingly, the patient's prostacyclin (PGI2) level.

Apart from the fact that the desirability as a therapeutic goal of improving the selective effect of a medicament is commonly acknowledged in the art, at the priority date it was known to a person skilled in the art that the desired inhibition of thromboxane A2 (TXA2) synthesis caused by aspirin is accompanied by the undesired side-effect of inhibition of endothelial prostacyclin (PGI2) activity. PGI2 is the major cyclooxygenase product of vascular endothelium and is a potent platelet inhibitor. As such, it plays a major role in regulating platelet activity and thromboxane levels in vivo. Consequently, the capability of aspirin to suppress thromboxane levels and its antiplatelet and antithrombotic effects may be attenuated by coincident inhibition of vascular prostacyclin activity and consequential reduction of prostacyclin (PGI2) levels (see eg (4), page 12S to page 13S, right hand column, end of the 2nd full paragraph, especially page 13S, left hand column, lines 13 to 27).

As can be derived from the comparative data in Table 2 of the present application and likewise from the disclosure in (4), it does not appear possible to achieve selective suppression of thromboxane levels with chronic administration of standard oral aspirin. In this respect it is noted that certain data provided in (4) suggest that oral aspirin is about as equally effective as an antithrombotic agent at doses at which prostaglandins are inhibited. These two different effects of oral aspirin do not appear to have necessarily been dependent on the administration of high dosage rates. The same effects were similarly observed, when aspirin was administered at doses as low as 35 mg/day for 7 days which are desirable for suppressing thromboxane levels (see especially page 13S, left hand column, end of the first full paragraph).

7.5. Thus, on the basis of the evidence available in the proceedings, the board is satisfied that, at the priority date, the low selective effect of oral aspirin in the suppression of thromboxane levels was recognised as being a problem from a therapeutic point of view for which the state of the art did not offer a satisfactory solution.

In view of the foregoing, the finding that dermal aspirin does not affect in any significant way prostaglandin levels, despite its capability of reducing the thromboxane levels by more than 90% (see eg Tables 1 and 2, Figures 1 and 2), cannot be seen merely as an extra effect obtained by way of a bonus in the context of solving the problem of suppressing thromboxane levels. It amounts rather to the achievement of a desirable therapeutic goal in its own right, particularly since many of the clinical conditions in which aspirin is used as an effective antithrombotic agent require the drug to be used over a long term or even indefinitely (see (4), especially page 12S, middle of right hand column). As mentioned above, at the priority date of the present application, this desideratum had not then, prima facie, actually been achieved.

7.6. In summary, the board reaches the conclusion that the complete solution of the stated problem cannot be inferred in an obvious manner from any of the citations available in the proceedings, since none of them would lead the skilled person to consider using dermal aspirin for the effective and selective suppression of thromboxane levels in a mammalian subject without simultaneously affecting prostacyclin levels. The non-obviousness of the use of dermal aspirin according to claim 1 also imparts an inventive step to the subject-matter of each of dependent claims 2 to 15 relating to specific elaborations of the use according to the independent claim.

Order

ORDER

For these reasons it is decided that:

1. The decision of the Examining Division is set aside.

2. The case is remitted to the department of the first instance with the order that a patent be granted on the basis of claims 1 to 15 of the "Main Request" filed during oral proceedings and a description to be adapted thereto.

Footer - Service & support
  • Service & support
    • Website updates
    • Availability of online services
    • FAQ
    • Publications
    • Procedural communications
    • Contact us
    • Subscription centre
    • Official holidays
    • Glossary
Footer - More links
  • Jobs & careers
  • Press centre
  • Single Access Portal
  • Procurement
  • Boards of Appeal
Facebook
European Patent Office
EPO Jobs
Instagram
EuropeanPatentOffice
Linkedin
European Patent Office
EPO Jobs
EPO Procurement
X (formerly Twitter)
EPOorg
EPOjobs
Youtube
TheEPO
Footer
  • Legal notice
  • Terms of use
  • Data protection and privacy
  • Accessibility